Trial · NCT03840148
Trial comparisons24
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
1 to 20 of 24
Download this page as JSON| Comparison | Source |
|---|---|
| Cefepime/VNRX-5133 (Taniborbactam) vs Meropenem: Microbiologic Success at Late Follow Up (LFU) in the ME Population | Trial comparisons |
| Cefepime/VNRX-5133 (Taniborbactam) vs Meropenem: Clinical Success at End of Treatment (EOT) in the microITT Population | Trial comparisons |
| Cefepime/VNRX-5133 (Taniborbactam) vs Meropenem: Composite Success at Late Follow Up (LFU) in the microITT Population | Trial comparisons |
| Cefepime/VNRX-5133 (Taniborbactam) vs Meropenem: Composite Success at End of Treatment (EOT) in the microITT Population | Trial comparisons |
| Cefepime/VNRX-5133 (Taniborbactam) vs Meropenem: Clinical Success at Test of Cure (TOC) in the microITT Population | Trial comparisons |
| Cefepime/VNRX-5133 (Taniborbactam) vs Meropenem: Composite Success at Test of Cure (TOC) in the Extended Microbiological Intent-to-treat (emicroITT) Population | Trial comparisons |
| Cefepime/VNRX-5133 (Taniborbactam) vs Meropenem: Clinical Success at Late Follow Up (LFU) in the CE Population | Trial comparisons |
| Cefepime/VNRX-5133 (Taniborbactam) vs Meropenem: Number of Patients With Treatment-Emergent Adverse Events | Trial comparisons |
| Cefepime/VNRX-5133 (Taniborbactam) vs Meropenem: Clinical Success at End of Treatment (EOT) in the Clinically Evaluable (CE) Population | Trial comparisons |
| Cefepime/VNRX-5133 (Taniborbactam) vs Meropenem: Clinical Success at Test of Cure (TOC) in the CE Population | Trial comparisons |
| Cefepime/VNRX-5133 (Taniborbactam) vs Meropenem: Microbiologic Success at Test of Cure (TOC) in the ME Population | Trial comparisons |
| Cefepime/VNRX-5133 (Taniborbactam) vs Meropenem: Number of Patients With Serious Adverse Events | Trial comparisons |
| Cefepime/VNRX-5133 (Taniborbactam) vs Meropenem: Composite Success at Late Follow Up (LFU) in the ME Population | Trial comparisons |
| Cefepime/VNRX-5133 (Taniborbactam) vs Meropenem: Investigator Opinion of Clinical Success at Test of Cure (TOC) in the microITT Population | Trial comparisons |
| Cefepime/VNRX-5133 (Taniborbactam) vs Meropenem: Microbiological Success at Late Follow Up (LFU) in the microITT Population | Trial comparisons |
| Cefepime/VNRX-5133 (Taniborbactam) vs Meropenem: deaths from any cause | Trial comparisons |
| Cefepime/VNRX-5133 (Taniborbactam) vs Meropenem: Composite Success at Test of Cure (TOC) in the ME Population | Trial comparisons |
| Cefepime/VNRX-5133 (Taniborbactam) vs Meropenem: Microbiologic Success at Test of Cure (TOC) in the microITT Population | Trial comparisons |
| Cefepime/VNRX-5133 (Taniborbactam) vs Meropenem: Composite Success at End of Treatment (EOT) in the Microbiologically-Evaluable (ME) Population | Trial comparisons |
| Cefepime/VNRX-5133 (Taniborbactam) vs Meropenem: Clinical Success at Late Follow Up (LFU) in the microITT Population | Trial comparisons |
trials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03840148/comparisons